Download full report with analyst certification and important disclosures
Feb 10 2026, 06:55 GMT
FY25 will provide confirmation that CRH continues to generate strong growth in revenue and adjusted EBITDA. 2026 is likely to see further delivery against this track record of growth, backed by the group's superior strategy and market-leading positions. There remains over 10% upside to our price target ($142).
Feb 10 2026, 06:55 GMT